Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multiple-Dose, Dose Escalation Study To Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Participants With Cervical High Grade Squamous Intraepithelial Lesions

NCT03697226 is registered in ClinicalTrials.gov with Antiva Biosciences as lead sponsor.

NCT NCT03697226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03697226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multiple-Dose, Dose Escalation Study To Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Participants With Cervical High Grade Squamous Intraepithelial Lesions
Lead sponsor
Antiva Biosciences
Phase
Phase 1
Overall status
Completed
Start date
December 21, 2018
Completion date
June 12, 2020
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cervical dysplasia, cervical neoplasm, cin - cervical intraepithelial neoplasia, high-grade cervical intraepithelial neoplasia, hiv negative, hsil of cervix, hsil, high grade squamous intraepithelial lesions, human papilloma virus